Preferences for Selecting and Initiating Long-Acting Injectable Antipsychotic Agents for the Treatment of Patients With Schizophrenia: Results From the US DECIDE Survey
Overall, results from DECIDE provide insight into the decision-making process of psychiatric clinicians when selecting an LAI and highlight opportunities to help clinicians deliver optimal care for patients with schizophrenia.
Authors
- Stephen Thompson (ORCID: https://orcid.org/0000-0001-9637-2041)
- Gregory D. Salinas (ORCID: https://orcid.org/0000-0001-8261-699X)
- Emily Belcher (ORCID: https://orcid.org/0000-0001-9652-9168)
- Mark Suett (ORCID: https://orcid.org/0000-0002-6840-1535)
- Ryan N. Hansen (ORCID: https://orcid.org/0000-0003-3887-1242)
- Dawn I. Velligan (ORCID: https://orcid.org/0000-0002-8213-1471)
- Kelli R. Franzenburg
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- Urology San Antonio (US)
- Teva Pharmaceuticals (United Kingdom) (GB)
- Health Outcomes Solutions (United States) (US)
- Teva Pharmaceuticals (United States) (US)
- Teva Pharmaceuticals (Czechia) (CZ)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Schizophrenia Bulletin Open
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1093/schizbullopen/sgaf001
- Citations
- 3
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.41
Funders
- Teva Pharmaceutical Industries